Adaptogenic Health Corp. Approved for Uplisting to OTCQB Venture Market

November 11, 2026 — Leads & Copy — Adaptogenic Health Corp. (CSE: ADPT) has been approved to uplist from the OTC Pink market to the OTCQB Venture Market, a development effective November 11, 2026. The Company will continue to trade in the United States under the ticker symbol “ADPGF” and on the Canadian Securities Exchange (CSE) under “ADPT”.

The OTCQB Venture Market, established in 2010, is recognized by the U.S. Securities and Exchange Commission (SEC) as an established public market and serves as a premier U.S. trading venue for early-stage and developing companies, aiming to enhance visibility and access for U.S. investors.

Adaptogenics Health Corp. anticipates that this uplisting will contribute to increased liquidity, improved transparency, and the attraction of a wider range of retail and institutional investors within the U.S. capital markets. The company also seeks to enhance its market position and shareholder value.

In addition to the uplisting, Adaptogenics Health Corp. has submitted an application for its common shares to be eligible for electronic clearing and settlement through The Depository Trust Company (DTC). This application is presently under review, and DTC eligibility has not yet been confirmed. The Company acknowledges that there is no assurance regarding the timing or certainty of DTC approval.

J. David Warren, CEO and Director of Adaptogenic Health Corp., stated that the uplisting represents a significant advancement in the Company's growth strategy. He emphasized that trading on the OTCQB Venture Market is consistent with the Company's dedication to enhancing shareholder value, increasing market visibility, and upholding high standards of corporate governance.

The OTCQB Venture Market provides a platform designed to support companies like Adaptogenics Health Corp. in their development and growth phases, offering a more structured environment for trading and investor relations.

Adaptogenics Health Corp. is focused on identifying, acquiring, designing, and advancing proprietary peptide and small molecule programs. The company's research and development efforts target areas such as metabolic health, muscle preservation, mitochondrial biology, and inflammation. It is also exploring delivery technologies to optimize the performance of potential molecules.

Alongside its existing nutraceutical operations, the Company is evaluating GLP-1 companion products. These products are intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies, and diminished physical function. Investors are encouraged to review the Company’s public filings, available on SEDAR+ at www.sedarplus.ca, for further details on its operations and strategy.

Source: Adaptogenic Health Corp.